0.3748
0.0037 (1.0%)
0.0037 (1.0%)
Upgrade to Real-Time
Afterhours (Closed)
Volume | 10,210,364 |
|
|||||
News | (3) | ||||||
Day High | 0.3857 | Low High |
|||||
Day Low | 0.3658 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Humanigen Inc | HGEN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.371 | 0.3658 | 0.3857 | 0.363 | 0.3711 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
14,315 | 10,210,364 | $ 0.3749393 | $ 3,828,267 | - | 0.35 - 18.22 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:49:33 | 1 | $ 0.3788 | USD |
Humanigen Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 26.47M | 70.63M | 59.27M | $ 3.60M | $ - | -4.05 | -0.10 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 4.32M | 0.80% |
Humanigen News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HGEN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.3702 | 0.4115 | 0.35 | 0.3752736 | 10,702,567 | 0.0046 | 1.24% |
1 Month | 0.50 | 0.57 | 0.35 | 0.4142001 | 13,790,490 | -0.1252 | -25.04% |
3 Months | 2.26 | 3.25 | 0.35 | 0.7557991 | 8,400,734 | -1.89 | -83.42% |
6 Months | 1.85 | 4.105 | 0.35 | 1.08 | 4,676,202 | -1.48 | -79.74% |
1 Year | 16.94 | 18.22 | 0.35 | 2.78 | 3,414,031 | -16.57 | -97.79% |
3 Years | 10.85 | 29.20 | 0.35 | 7.12 | 2,503,084 | -10.48 | -96.55% |
5 Years | 10.85 | 29.20 | 0.35 | 7.12 | 2,503,084 | -10.48 | -96.55% |
Humanigen Description
Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. |